Scott G. Weiner

Scott G. Weiner

Auto-generated profile, based on publicly available information

Scott G. Weiner

Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
UHUdo Hoffmann
Udo Hoffmann
QTQuynh A. Truong
Quynh A. Truong
DSDavid A. Schoenfeld
David A. Schoenfeld
ECEric T. Chou
Eric T. Chou
PWPamela K. Woodard
Pamela K. Woodard
JUJames E. Udelson
James E. Udelson
It is unclear whether an evaluation incorporating coronary computed tomographic angiography (CCTA) is more effective than standard evaluation in the emergency department in patients with symptoms suggestive of acute coronary syndromes. In this multicenter trial, we randomly assigned patients 40 to 74 years of age with symptoms suggestive of acute coronary syndromes but without ischemic electrocardiographic changes or an initial positive troponin test to early CCTA or to standard evaluation in the emergency department on weekdays during daylight hours between April 2010 and January 2012. The primary end point was length of stay in the hospital. Secondary end points included rates of discharge from the emergency department, major adverse cardiovascular events at 28 days, and cumulative costs. Safety end points were undetected acute coronary syndromes. The rate of acute coronary syndromes among 1000 patients with a mean (±SD) age of 54±8 years (47% women) was 8%. After early CCTA, as compared with standard evaluation, the mean length of stay in the hospital was reduced by 7.6 hours (P<0.001) and more patients were discharged directly from the emergency department (47% vs. 12%, P<0.001). There were no undetected acute coronary syndromes and no significant differences in major adverse cardiovascular events at 28 days. After CCTA, there was more downstream testing and higher radiation exposure. The cumulative mean cost of care was similar in the CCTA group and the standard-evaluation group ($4,289 and $4,060, respectively; P=0.65). In patients in the emergency department with symptoms suggestive of acute coronary syndromes, incorporating CCTA into a triage strategy improved the efficiency of clinical decision making, as compared with a standard evaluation in the emergency department, but it resulted in an increase in downstream testing and radiation exposure with no decrease in the overall costs of care. (Funded by the National Heart, Lung, and Blood Institute; ROMICAT-II ClinicalTrials.gov number, NCT01084239.)

1 January 2020 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
SWScott G. Weiner
Scott G. Weiner
OBOlesya Baker
Olesya Baker
DBDana Bernson
Dana Bernson
JSJeremiah D. Schuur
Jeremiah D. Schuur

3 March 2015 in JAMA
Verified
Journal Article
Closed access
PDF file
RHRebecca L. Haffajee
Rebecca L. Haffajee
AJAnupam B. Jena
Anupam B. Jena
SWScott G. Weiner
Scott G. Weiner
This Viewpoint describes the benefits of, evidence behind, and prescriber concerns with mandates, and recommends policies that may increase effective use of pre

23 June 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MYMark Yeager
Mark Yeager
EWElizabeth M. Wilson-Kubalek
Elizabeth M. Wilson-Kubalek
SWScott G. Weiner
Scott G. Weiner
PBPatrick O. Brown
Patrick O. Brown
ARAlan Rein
Alan Rein
We have used electron cryo-microscopy and image analysis to examine the native structure of immature, protease-deficient (PR − ) and mature, wild-type (WT) Moloney murine leukemia virus (MuLV). Maturational cleavage of the Gag polyprotein by the viral protease is associated with striking morphological changes. The PR − MuLV particles exhibit a rounded central core, which has a characteristic track-like shell on its surface, whereas the WT MuLV cores display a polygonal surface with loss of the track-like feature. The pleomorphic shape and inability to refine unique orientation angles suggest that neither the PR − nor the WT MuLV adheres to strict icosahedral symmetry. Nevertheless, the PR − MuLV particles do exhibit paracrystalline order with a spacing between Gag molecules of ≈45 Å and a length of ≈200 Å. Because of the pleomorphic shape and paracrystalline packing of the Gag–RNA complexes, we raise the possibility that assembly of MuLV is driven by protein–RNA, as well as protein–protein, interactions. The maturation process involves a dramatic reorganization of the packing arrangements within the ribonucleoprotein core with disordering and loosening of the individual protein components.

1 September 2015 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
JHJason A. Hoppe
Jason A. Hoppe
LNLewis S. Nelson
Lewis S. Nelson
JPJeanmarie Perrone
Jeanmarie Perrone
SWScott G. Weiner
Scott G. Weiner
NRNiels K. Rathlev
Niels K. Rathlev
AKAndrea Koploy
Andrea Koploy

21 March 2025 in Anesthesiology
Verified
Journal Article
Open access
TBTodd Bertoch
Todd Bertoch
DDDominick D’aUnno
Dominick D’aUnno
JMJessica McCoun
Jessica McCoun
DSDaneshvari Solanki
Daneshvari Solanki
LTLouise Taber
Louise Taber
SWScott G. Weiner
Scott G. Weiner
Background: Opioids are effective for treating acute pain but have safety, tolerability, and addiction concerns while non-opioid analgesics have limited efficacy. Suzetrigine, an oral, non-opioid, small molecule, selectively inhibits the voltage-gated sodium channel 1.8 (NaV1.8) and has potential to provide efficacious and safe relief for acute pain, without addiction concerns. Methods: To evaluate suzetrigine for treatment of acute pain, we conducted two phase 3, randomized, double-blind, placebo- and active-controlled trials in adults with moderate-to-severe acute pain on the verbal categorical rating scale and ≥4 on the numeric pain rating scale (NPRS) after abdominoplasty (N=1118) or bunionectomy (N=1073). After surgery, participants were randomized to suzetrigine (100mg then 50mg every 12hrs), hydrocodone bitartrate/acetaminophen (HB/APAP; 5/325mg every 6hrs), or placebo for 48 hours. The primary endpoint was time-weighted sum of the pain intensity difference in NPRS from 0-48hrs (SPID48) versus placebo. Key secondary endpoints were SPID48 versus HB/APAP and time to ≥2-point reduction in NPRS from baseline versus placebo. Results: The primary endpoint was achieved in both trials with suzetrigine demonstrating statistically significant and clinically meaningful reduction in pain versus placebo. The least squares mean difference in SPID48 between suzetrigine and placebo was 48.4 (95%CI:33.6,63.1;P<0.0001) after abdominoplasty and 29.3 (95%CI:14.0,44.6; P=0.0002) after bunionectomy. Neither trial achieved the first key secondary endpoint of superiority of suzetrigine versus HB/APAP on SPID48. For the second key secondary endpoint of time to ≥2-point reduction in NPRS, suzetrigine had a more rapid onset of clinically meaningful pain relief versus placebo after abdominoplasty (119min versus 480mins, nominal P<0.0001) and bunionectomy (240mins versus 480mins, nominal P=0.0016). Adverse events (AEs) were similar to those seen in post-surgical settings. Conclusions: As compared with placebo, suzetrigine reduced moderate-to-severe acute pain over 48 hours after abdominoplasty or bunionectomy. Pain reduction with suzetrigine was similar to that with HB/APAP. Suzetrigine was associated with adverse events that were mild to moderate in severity. Clinicaltrials.gov Registration: NCT05558410 and NCT05553366